Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | NOS3 | P29474 | 2/20 | 0.48 |
| ▸ | NOS2 | P35228 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30718977 | 1.00 | KMT2A (0.49) | KMT2AMEN1NOS3NOS2NOS1 | |
| SCHEMBL3625881 | 0.85 | HSP90AB1 (0.46) | KMT2AMEN1NOS3NOS2NOS1 | |
| SCHEMBL1885381 | 0.83 | POLB (0.65) | KMT2AMEN1POLBAPOBEC3GHSP90AB1 | |
| SCHEMBL21035298 | 0.80 | NOS3 (0.46) | KMT2AMEN1NOS3NOS2NOS1 | |
| SCHEMBL191585 | 0.76 | KMT2A (0.49) | KMT2AMEN1POLBHSP90AB1HTT | |
| SCHEMBL30591631 | 0.76 | HSP90AB1 (0.39) | KMT2AMEN1NOS3NOS2NOS1 | |
| SCHEMBL163966 | 0.76 | HSP90AB1 (0.39) | KMT2AMEN1NOS3NOS2NOS1 | |
| SCHEMBL29368005 | 0.76 | KMT2A (0.49) | KMT2AMEN1POLBHSP90AB1HTT | |
| SCHEMBL5766295 | 0.74 | POLB (0.48) | KMT2AMEN1POLBAPOBEC3GHSP90AB1 | |
| Hydrochloric Acid SCHEMBL11426179 | 0.74 | KMT2A (0.47) | KMT2AMEN1POLBHSP90AB1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| CN-112469719-B | Heterocondensed pyridone compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3797107-B1 | HETEROCONDENSED PYRIDONE COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2022-08-10 | — | — | EP | disclosed |
| US-20210206759-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-07-08 | — | — | US | disclosed |
| US-20210206759-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-07-08 | — | — | US | disclosed |
| EP-3797107-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2021-03-31 | — | — | EP | disclosed |
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-7998969-B2 | enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases | ROCHE PALO ALTO LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2009094279-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20080146595-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-4565864-A | INTERMEDIATES FOR BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4503050-A | BRONCHODILATORS | RIKER LABORATORIES, INC. (US) | 1985-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | KMT2A 2017/4885MEN1 1802/4885NOS3 2046/4885 |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | IDH1, IDH2, IDH3A | KMT2A 506/4885MEN1 1149/4885NOS3 1789/4885 |
| US-20080146595-A1 | Non-nucleoside reverse transcriptase inhibitors | NQO2, SAMHD1, POLR2A | KMT2A 703/4885MEN1 4596/4885NOS3 290/4885 |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | KMT2A 1923/4885MEN1 3806/4885NOS3 2804/4885 |
| US-20210206759-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | IDH1, IDH2, IDH3A | KMT2A 506/4885MEN1 1149/4885NOS3 1789/4885 |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | KMT2A 1923/4885MEN1 3806/4885NOS3 2804/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | KMT2A 2017/4885MEN1 1802/4885NOS3 2046/4885 |
| US-20110112077-A1 | Quinolizidinone m1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | KMT2A 1726/4885MEN1 3473/4885NOS3 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.